Le Lézard
Classified in: Health
Subjects: AWD, NPT, HSP

Myriam Hemberger Receives 2019 March of Dimes Prize For Breakthrough Research On Placental Biology


BALTIMORE, April  29, 2019 /PRNewswire/ -- For her pioneering research to explain the biology of the placenta, the crucial organ for pregnancy in humans and most other mammals, Myriam Hemberger, PhD, has been awarded the 2019 March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology. March of Dimes is the leading nonprofit for the health of moms and babies.

Myriam Hemberger, PhD, Professor in the Departments of Biochemistry & Molecular Biology and Medical Genetics, Cumming School of Medicine, University of Calgary, Canada, has received the 2019 March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology for pioneering research on the biology of the placenta, the crucial organ for pregnancy in humans and most other mammals.

Dr. Hemberger, Professor in the Departments of Biochemistry & Molecular Biology and Medical Genetics at the Cumming School of Medicine, University of Calgary, Canada, is a world leader in the study of placental development, with an emphasis on the impact of the placenta on successful pregnancy outcome. Over the years, she has made seminal contributions to our understanding of the epigenetic gene regulation that leads to successful formation of a placenta in the uterus.

Her 2018 paper in Nature on the prevalence of placental defects in mouse embryos with severe developmental defects was a game changer for the field as it highlighted the potential contribution of the placenta to malformations of the fetus in a far greater proportion of cases than previously thought.

As part of this work, Dr. Hemberger and her colleagues also have done groundbreaking research that uncovered a close connection between placental defects and congenital heart disease, for which they won the inaugural Magee Prize from the Richard K. Mellon Foundation in 2018.

"Dr. Hemberger has made amazing advances in our understanding of pregnancy complications and developmental defects," says Kelle H. Moley, MD, Senior Vice President and Chief Scientific Officer for March of Dimes. "We are excited to honor her with our top prize in research. Dr. Hemberger's work to explain events that take place early in development, including the heart-placenta connection, will make it possible in the future for improved diagnosis and treatment for healthier moms and babies."

The March of Dimes and Richard B. Johnston, Jr., MD Prize in Developmental Biology is awarded annually to an outstanding scientist who has profoundly advanced the science that underlies our understanding of prenatal development and pregnancy.  Shortly before Dr. Jonas Salk's death in 1995, March of Dimes created this Prize as a tribute to him.  Since 1996, the Prize has been awarded 23 times, 10 times to a single individual and 13 times to a dyad working in the same area. A large number of recipients have subsequently garnered or previously earned other major prizes, including the Nobel Prize. 

A native of Germany, Dr. Hemberger earned a diploma in biology and her PhD at the University of Freiburg with work carried out at the Max-Planck-Institute for Molecular Genetics in Berlin. She completed postdoctoral training at the Samuel Lunenfeld Research Institute in Toronto and at the University of Calgary. 

In 2004, as an MRC Career Development Fellow, Dr. Hemberger started an independent research group at the Babraham Institute in Cambridge, England, UK. She was awarded a tenured position there in 2009 and was promoted to senior group leader at Babraham's Epigenetics Programme in 2014. She moved to Canada to take up her current post in 2018.

Currently, she is also the Theme Lead of the Genes, Development & Health research group at the Alberta Children's Hospital Research Institute (ACHRI). She also has been a core member of the Centre for Trophoblast Research (CTR) at the University of Cambridge since its inauguration in 2008, and has served on the CTR's Board of Managers for the last five years. In 2018, Dr. Hemberger was awarded the Athena SWAN Best Practice Award for pioneering initiatives and commitment to women's careers in science. She received the IFPA Award in Placentology in 2007 for her contributions to the field.

Dr. Hemberger will deliver the 24th annual Prize Lecture today during the 2019 Pediatric Academy Societies annual meeting at the Baltimore Convention Center. At a dinner ceremony this evening, she will receive the Prize, which is a cash award of $150,000 and a silver medal in the design of the Roosevelt dime, in honor of President Franklin Delano Roosevelt, who founded March of Dimes. 

About March of Dimes

March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Find us on Facebook and follow us on Instagram and Twitter.

March of Dimes Foundation Logo (PRNewsfoto/March of Dimes Foundation)

SOURCE March of Dimes


These press releases may also interest you

at 07:55
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...



News published on and distributed by: